fda label semaglutide naion warning 2025 linked to increased risk of vision loss in diabetes patients Ozempic Vision Loss Warning: EMA

William Valentine is an employee of Ossian Health Economics and Communications, which received consulting fees from Novo Nordisk A/S to support preparation of the analysis

Memory that feels foggy

To note, with the G-agonists, GIP receptors in the brain may respond differently than those peripherally, with less GI side effects

It indicates a move towards a more inclusive healthcare model, where weight management is not just a personal responsibility but a critical component of holistic health that is supported and facilitated through financial planning

Three years later, in 2024, the FDA also approved it to reduce the risk of cardiovascular death, heart attack, and stroke for people who have obesity or overweight as well as cardiovascular disease